Treatment of Primary Immunodeficiency Diseases and Bone Marrow Transplantation
Dr. Gaurav Kharya is an internationally recognized expert in pediatric hematology, oncology, immunology, and bone marrow transplant (BMT). With over 20 years of experience, he has pioneered transformative treatments, particularly in hematopoietic stem cell transplantation, to address complex hematological disorders like sickle cell disease (SCD), thalassemia, leukemia, and immune deficiencies.
Dr. Kharya’s extensive medical training spans across some of the world’s leading institutions, including Sir Ganga Ram Hospital in India, The Great North Children’s Hospital in the UK, and Imperial College London. He currently serves as the Clinical Lead at the Center for Bone Marrow Transplant and Cellular Therapy at Apollo Hospitals, New Delhi, where he has successfully performed over 1000 BMTs, including more than 100 transplants for SCD patients, making him a leader in this field. He is also the founder and director of Cellogen Therapeutics, a company focused on advancing cell and gene therapy in India.
Expertise in Haploidentical Transplants
Dr. Kharya is widely regarded for his expertise in haploidentical transplants, a form of allogeneic BMT where the donor is a partial genetic match, usually a family member. This method has emerged as a vital option for patients who lack a fully matched donor. Dr. Kharya’s groundbreaking work has helped establish haploidentical transplants as a viable and highly effective treatment, especially for patients with rare or life-threatening blood disorders. His efforts have made bone marrow transplants more accessible and affordable, contributing to the increased survival rates and improved quality of life for his patients.
Advocate for Cutting-edge Therapies: CAR T-Cell Therapy and Gene Manipulation
In addition to bone marrow transplants, Dr. Kharya is a strong advocate for innovative therapies such as CAR T-cell therapy and gene manipulation.